Hymenochirin-1B [P5K,E6K]

General Information


DRACP ID  DRACP02302

Peptide Name   Hymenochirin-1B [P5K,E6K]

Sequence  IKLSKKTKDNLKKVLKGAIKGAIAVAKMV

Sequence Length  29

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic (Derived from Hymenochirin-1B)

Type  Synthetic peptide

Classification

  

Active ACP Membrane lysis



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
A549 Lung adenocarcinoma Carcinoma LC50=1.1 ± 0.1 μM CellTiter-Glo Luminescent Cell Viability assay 24 h 1

Hemolytic Activity  Human erythrocytes: LC50=137 ± 11 μM

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02302

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C141H261N39O35S

Absent amino acids  CEFHPQRWY

Common amino acids  K

Mass  359457

Pl  11.34

Basic residues  9

Acidic residues  1

Hydrophobic residues  13

Net charge  8

Boman Index  -1817

Hydrophobicity  7.59

Aliphatic Index  124.48

Half Life 
  Mammalian: 20 hour
  Yeast: 30 min
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  5

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 24185042

Title  Anti-tumor activities of the host-defense peptide hymenochirin-1B

Doi 10.1016/j.regpep.2013.10.006

Year  2013

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_4423

DRACP is developed by Dr.Zheng's team.